Pharming Group (NASDAQ:PHAR) Sees Large Decline in Short Interest

Pharming Group (NASDAQ:PHAR) saw a significant decrease in short interest during the month of May. As of May 15th, there was short interest totalling 1,300 shares, a decrease of 18.8% from the April 30th total of 1,600 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 5,100 shares, the short-interest ratio is presently 0.3 days.

Analyst Upgrades and Downgrades

PHAR has been the topic of several research reports. HC Wainwright reissued a “buy” rating and issued a $37.00 target price on shares of Pharming Group in a report on Thursday, March 20th. Oppenheimer upped their target price on Pharming Group from $30.00 to $39.00 and gave the company an “outperform” rating in a report on Friday, March 14th.

Pharming Group Stock Up 8.3%

PHAR opened at $11.48 on Tuesday. The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41. The firm has a market cap of $781.00 million, a P/E ratio of -44.15 and a beta of -0.08. Pharming Group has a 52 week low of $6.65 and a 52 week high of $11.72. The business’s fifty day simple moving average is $9.00 and its 200 day simple moving average is $8.92.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.03. The business had revenue of $79.09 million for the quarter, compared to analyst estimates of $67.74 million. Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. As a group, equities research analysts anticipate that Pharming Group will post -0.2 EPS for the current fiscal year.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.